GE Healthcare of Chalfont St. Giles, U.K., has licensed technology related to molecular radiopharmaceuticals from the Medical College of Wisconsin in Milwaukee.
The technology involves molecular probes that bind to dead and dying cells, making them useful for detecting acute cell injury and cell death. When the active component of the molecule is attached to a radioactive tracer, it can be used in PET or SPECT procedures to produce 3D images of where cell death is occurring.
The technology could allow oncologists to rapidly monitor tumor response to a specific therapy, or enable rapid diagnosis of myocardial infarction, according to the Medical College of Wisconsin.
Related Reading
GE sues Danish radiologist, December 23, 2009
Lawsuit hits GE in Alabama CT overdose case, December 18, 2009
GE expands apps for Centricity PACS, December 15, 2009
GE highlights dual-energy CT, MRI elastography at RSNA booth, November 30, 2009
GE to debut MR elastography, November 24, 2009
Copyright © 2009 AuntMinnie.com
